Abeona Therapeutics Inc.
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious and rare diseases. Its commercial product, ZEVASKYN, is an autologous gene-modified cellular sheet therapy approved in the United States for wounds in adults and children with… From the company’s description.
Over the twelve months to Jun 30, 2026, Abeona Therapeutics Inc. reported revenue of $25.52M, up 6280.0% from a year earlier, and a net loss of $62.89M. Its operating margin was −327.6%, and operations used $76.44M in cash. In fiscal 2025, it reported revenue of $5.82M and net income of $71.18M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Abeona Therapeutics Inc. does
In the company’s own words
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious and rare diseases. Its commercial product, ZEVASKYN, is an autologous gene-modified cellular sheet therapy approved in the United States for wounds in adults and children with recessive dystrophic epidermolysis bullosa; it is manufactured from a patient’s own skin cells and administered through qualified treatment centers. Abeona also develops adeno-associated virus gene therapies for ophthalmic diseases, including candidates for X-linked retinoschisis, Stargardt disease and autosomal dominant optic atrophy, using its AIM capsid technology. The company manufactures ZEVASKYN and clinical-stage vectors at its Cleveland facility and commercializes ZEVASKYN directly, while also licensing technology and partnering on selected programs. Its pipeline includes programs licensed to Ultragenyx and Taysha, and Beacon holds a non-exclusive license to use the AAV204 capsid for selected targets. Abeona treated its first ZEVASKYN patient in the fourth quarter of 2025 and had activated four qualified treatment centers by March 2026. Its website is www.abeonatherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CLEVELAND, OH
- Fiscal year end
- December
- CIK
- 318306
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Abeona Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Abeona Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Abeona Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Abeona Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Abeona Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”